Solid-Phase Synthesis of the Hainantoxin-III and Its Antinociception Analysis in the Acid-Induced Writhing Responses of Mice

YU LIU*, ZHE WU, XIAOHONG XUN, DONGSONG NIE and YANG XIANG

College of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, P.R. China

*Corresponding author: E-mail: hiliu2000@yahoo.com.cn

(Received: 18 February 2012;

Accepted: 17 December 2012)

AJC-12561

Hainantoxin-III (HNTX-III), a neurotoxic peptide from the Chinese spider *Ornithoctonus hainana* Liang, was synthesized by Fmoc solid-phase peptide synthesis method. The solid-phase carrier was rink amide resin. The synthetic peptide was cleaved from the resin and deprotected by a 90 % trifluoroacetic acid solution containing 5 % thioanisole, 3 % ethanedithiol and 2 % anisole. The product was purified by RP-HPLC and then incubated with glutathione and reduced glutathione to form the correct disulfide bond linkages. The refolded synthetic peptide was purified by RP-HPLC and then co-eluted with native hainantoxin-III. The results indicated that the synthetic hainantoxin-III has the same chemical and conformational structure as those of the native hainantoxin-III from the spider. In this study, we use the synthetic toxin to investigate the antinociceptive effect of intramuscular injected hainantoxin-III in acetic acid writhing reflex test in mice and to compare its efficacy with morphine. The study confirms that intramuscular injection of hainantoxin-III, like morphine, has antinociceptive effect in the mice model of inflammatory pain, suggesting that it may be a potential drug in clinical control of inflammatory pain.

Key Words: Hainantoxin-III, Synthesis, Antinociception.

INTRODUCTION

Hainantoxin-III (HNTX-III) is a 33-residue blocking of sodium channels that was isolated from the venom of the Chinese bird spider *Ornithoctonus hainana* Liang¹ which has recently been identified as a typical inhibitor cystine knot motif. The toxin has a high proportion of basic residues and it is cross-linked by three conserved intramolecular disulfide bond. The linkage pattern of disulfide bridges in HNTX-III is I-IV, II-V and III-VI as assigned by partial reduction and sequence analysis and the C-terminal ends amidated (Fig. 1). It has been shown to specifically inhibit the neuronal tetrodotoxin-sensitive (TTX-S) voltage-gated sodium channels (VGSCs) in adult rat dorsal root ganglion (DRG) neurons with IC₅₀ values of 30 nM and seem to interact with neurotoxin receptor site 1 through a mechanism quite similar to that of TTX without affecting the activation and inactivation kinetics. The HNTX-III did not affect Ca²⁺ channels (both high voltage activated and low voltage activated types) nor tetrodotoxin-resistant VGSCs^{2,3}.

In this paper, we report the solid-phase chemical synthesis of HNTX-III with the Fmoc method. The objectives of this work are to provide sufficient materials to enable extensive studies of this toxin. We also report here the investigation of the optimal conditions for the correct formation of the three bonds of the synthesized HNTX-III. The results of the chemical and co-elution analysis and the electro-physiological testing

of the final product are also reported. The purpose of the toxin synthesis was therefore to investigate the antinociceptive effect of intramuscular administrated HNTX-III in acetic acid writhing test in mice and to compare its efficacy with morphine.

Fig. 1. Amino acid sequence and disulfide bond arrangements in HNTX-III

EXPERIMENTAL

DTT, trifluoroacetic acid (TFA), glutathione (GSSG) and reduced glutathione (GSH) were products of Sigma. PAL-PEG-PS resin, Fmoc-AA-OH, HOBt and TBTU were from ABI Ltd; acetonitrile and methanol (HPLC grade) were purchased from Linhai Chemical. All other reagents were of analytical grade.

Peptide synthesis, folding and purification: HNTX-III was synthesized starting from a poly(ethylene glycol) polystyrene resin equipped with a peptide amide linker (Fmocpeptide amide linker-polyethylene glycol-polystyrene (PAL-PEG-PS) amide resin, Applied Biosystems) on an automatic peptide synthesizer (PerSeptive Biosystems) using an Fmoc/*tert*-butyl strategy and HOBt/TBTU/NMM coupling

method. All amino acids were purchased from Chemassit Corp. and side chains were protected as follows: trityl for Asn, Cys and His; *tert*-butyl ester for Asp and Glu; *tert*-butyl ether for Ser, Thr and Tyr; 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for Arg; butoxycarbonyl for Trp and *tert*-butyloxycarbonyl for Lys. Peptide synthesis was accomplished on a 0.10 mmol scale. The terminal Fmoc group was removed by treatment with 1:4 piperidine/*N,N*-dimethylformamide (v/v). After completion of synthesis, the peptide was cleaved from the resin with simultaneous removal of side chain protective groups by treatment with reagent K (82.5 % trifluoroacetic acid, 5 % double distilled water, 5 % phenol, 5 % thioanisole and 2.5 % ethanedithiol) for 2 h at room temperature. The resin was then filtered and the free peptide was precipitated in cold ether at 4 °C. After centrifugation and washing once with cold ether, the peptide was dissolved in 20 % acetic acid and lyophilized. The reduced peptides were purified by semi-preparative reverse-phase HPLC using a 42 min linear gradient of 10-50 % eluent B (0.1 % trifluoroacetic acid in acetonitrile) in eluent A (0.1 % trifluoroacetic acid in double distilled water) over 42 min on a column at 2 mL/min flow rate. Peaks were analyzed by analytical HPLC and more than 95 % pure fractions were pooled and lyophilized. The linear peptides were oxidized with glutathione and purified using the method recently described by Zhu *et al.*⁴. The molecular weights of the reduced peptides or oxidized peptides were checked by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry on a Voyager-DETM STR Biospectrometry™ workstation. For HNTX-III, the measured molecular mass corresponded to the predicted value within 1.0 unit, consistent with the correctness of the sequence and the complete removal of all side chain protection groups.

Co-elution synthetic HNTX-III and native HNTX-III by HPLC: The mixture, 1 mg synthetic HNTX-III and 1 mg native HNTX-III, was analyzed by HPLC. Elution was performed with a linear gradient from 10-50 % buffer B (Buffer A: water with 0.1 % trifluoroacetic acid; buffer B: acetonitrile, 0.1 % trifluoroacetic acid) over 42 min.

Electro-physiological experiments: The whole cell patch clamp experiments were made from rat DRG neurons as described previously⁵. Rat DRG neurons were acutely dissociated and maintained in a short term primary culture using the method described by Hu and Li⁶. In brief 30 day-old adult Sprague-Dawley rats of either sex were killed by decapitation and the dorsal root ganglia were isolated quickly from the spinal cord. Then they were transferred into Dulbecco's modified eagle's medium containing trypsin (0.5 mg/mL, type III, Sigma), collagenase (1.0 mg/mL, type IA, Sigma) and DNase (0.1 mg/mL, type III, Sigma) to incubate at 34 °C for 0.5 h. Trypsin inhibitor (1.5 mg/mL, type II-S, Sigma) was used to terminate enzyme treatment. The DRG cells were transferred into 35 mm dishes (Corning, Sigma) with the culture medium and incubated in a CO₂ incubator (5 % CO₂, 95 % air at 37 °C) for 1-4 h before the patch clamp experiment.

Patch clamp experiments were performed at room temperature (20-25 °C) under the whole cell patch clamp configuration. Patch pipettes (2-3 µm diameter) were pulled from borosilicate glass capillary tubing by using a two-step

vertical puller (PC-10, Narishige, Olympus) and heat-polished with a microforge (MF-900, Narishige). Patch pipettes with resistances of 1.0-2.0 megaohms were used. The series resistance was compensated 65-70 % and linear capacitive and linear leakage currents were digitally subtracted by a P/4 procedure. Sodium currents were filtered at 10 kHz and digitized at 3 kHz with an EPC-9 patch clamp amplifier (HEKA Electronics, Germany). Experimental data were collected and analyzed by using the program Pulse/Pulsefit 8.0 (HEKA Electronics, Lambrecht/Pfalz, Germany). The patch pipettes contained 135 mM CsF, 10 mM NaCl, 5 mM HEPES with the pH adjusted to 7.0 with 1 M CsOH. The external bathing solution contained 30 mM NaCl, 5 mM CsCl, 25 mM D-glucose, 1 mM MgCl₂, 1.8 mM CaCl₂, 5 mM HEPES, 20 mM tetraethylammonium chloride, 70 mM tetramethylammonium chloride with the pH adjusted to 7.40 with 1 M tetraethylammonium hydroxide. Peptide toxin was dissolved in external solution and about a 10 µL volume was applied by pressure injection with a microinjector (IM-5B, Narishige). All chemical reagents were purchased from Sigma.

Acetic acid writhing reflex test: Adult Kunming mice (either sexes, weighting 20-22 g) were used for this behavioural test. Animals were provided by the Hunan slack-kinda experimental animal limited company and use of the animal was reviewed and approved by the Animal Care and Use Committee. Mice were divided into three groups of eight each. Group one received control, group one received synthetic HNTX-III and the remaining group received morphine. 15 min later, 0.2 mL of 0.6 % acetic acid was injected into the abdominal cavity. After 5 min lag time, the number of abdominal contractions (writhing movement) was observed for 15 min and record. Percentage inhibition of writhing movement was then calculated from the values obtained.

Statistics: Data were expressed as means ± SEM and examined by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison test. A *p*-value of less than 0.05 was considered significant.

RESULTS AND DISCUSSION

Peptide synthesis and characterization: Solid-phase synthesis of HNTX-III, using Fmoc protected amino acids and HOBt/TBTU coupling, yielded a major product as revealed by reverse-phase HPLC analysis and MALDI-TOF mass spectrometry. The purified reduced peptide was folded/oxidized in buffer 0.1 M tris-HCl, 0.1 M NaCl, pH 7.4, containing 5 mM GSH, 0.5 mM GSSG for 24 h at room temperature. Purified products were homogeneous in analytical reverse-phase HPLC (Fig. 2) and their masses (3615 Da, 3609 Da, for reduced HNTX-III, oxidized HNTX-III, respectively, Fig. 3) were in good accordance with the theoretical masses.

Bioactivity analysis of the synthesized HNTX-III: The biological activities of the synthesized HNTX-III were studied by testing their capacity to inhibit the TTX-S sodium channels in rat DRG neurons. The dose-response curves shown in Fig. 4 illustrate the block of sodium channels at peptide concentrations ranging from 1 nM to 10 µM. The IC₅₀ values of 34.2 nM were estimated for the synthesized HNTX-III. The value was approximately similar to that of native HNTX-III.

Fig. 2. Analytical reversed-phase HPLC chromatograms of (A) crude product; (B) reduced synthetic HNTX-III after oxidation 5 min; (C) reduced synthetic HNTX-III after oxidation 24 h; (D) the mixture of synthesized and native HNTX-III at an equal amount

Fig. 3. MALDI-TOF mass spectra of HNTX-III (A) reduced synthetic HNTX-III; (B) oxidation synthetic HNTX-III. The mass spectrometry results show that the oxidized synthetic HNTX-III was formed three-disulfide bridged

Fig. 4. Inhibition potency of HNTX-III on TTX-S Na^+ currents in rat DRG cells. Dose-dependent inhibition of peptide on TTX-S Na^+ currents. Every data point (mean $\pm$ SE), which came from three to eight cells, shows current relative to control. The value was approximately similar to that of native HNTX-III ($\text{IC}_{50} = 34.2 \text{ nM}$)

HNTX-III significantly reduced writhings and stretchings induced by the acetic acid (Fig. 5). The protective effect was

dose dependent with 18.06 % ($p < 0.05$) reduction observed for 20.0 $\mu\text{g/kg}$ and 65.16 % ($p < 0.01$) seen for 100 $\mu\text{g/kg}$ dose. The HNTX-III had an ED_{50} of 65.0 $\mu\text{g/kg}$ with a confidence limit of 20-100 $\mu\text{g/kg}$. Morphine (a centrally acting analgesic) had 57.42 % ($p < 0.01$) inhibition with 50 $\mu\text{g/kg}$. From the analgesic effect, the analgesic effect of 100 mg/kg of HNTX-III was equal to the analgesic effect of the 50 mg/kg of morphine.

Fig. 5. Column graph shows the influence of HNTX-III on mouse writhing reflex induced by acetic acid. Group differences were considered statistically significant at $p < 0.05$. ** $p < 0.01$; * $p < 0.05$

The acetic acid-induced writhing reaction in mice, described as a typical model for inflammatory pain, has long been used as a screening tool for evaluation of analgesic or antiinflammatory agents⁷. Major transmission pathway of the inflammatory pain has been documented as the pathway comprising peripheral polymodal receptors around small vessels that signal the central nervous system *via* sensory afferent C-fibers that enter the dorsal horn⁸. Bradykinin⁹, substance P¹⁰ and prostaglandins¹¹ were documented as mediators involved in the writhing responses induced by acetic acid, acetylcholine or phenylquinone. Berkenkopf reported PGI₂ as a major prostanoid, based on the detection of 6-keto-PGF₁ α in the exudates of mice undergoing an acetic acid-induced writhing response. The Yuri Ikeda's study is the first to demonstrate the contribution of the VR1 receptor to the acid-induced writhing response¹². The analgesic potential of the HNTX-III was shown by acetic acid test to be effective. HNTX-III has been shown to specifically inhibit the mammal neuronal TTX-S sodium channels in DRG cells², meaning TTX-S sodium channels was contributed to the acid-induced writhing response and HNTX-III is a good pain drug lead.

ω -Conotoxin MVIIA as a new non-morphine analgesics, respectively, in 2004 and 2005 the USFDA and the European Union (EC) approved as a treatment for chronic pain analgesic drugs (Ziconotide) listed. However, the antinociception induced by ω -conotoxin MVIIA were accompanied with motor dysfunction, such as whole body shaking, circling, ataxia and tail wiggling and so on characteristic body shaking behaviours as described previously¹³⁻¹⁵ during the 1 h observation period. These side-effects became more evident with the doses of ω -conotoxin MVIIA increasing. In contrast, HNTX-III did not have those side-effects at the doses of 10-4000 $\mu\text{g/kg}$. On the other hand, ω -conotoxin MVIIA need to intrathecal injection, HNTX-III can be intramuscular injected. It is very beneficial on drug delivery.

In summary, the neurotoxic peptide HNTX-III has been synthetic by solid phase method with Fmoc method. The synthesized toxin has been proved to have the same chemical and three-dimensional structure and to possess the same

biological activity. The study confirms that intramuscular injection of HNTX-III, like morphine, has antinociceptive effect in the mice model of acid-induced inflammatory pain, suggesting that it may be a potential drug in clinical control of pain. As the new TTX-S sodium channel antagonists, perhaps HNTX-III possess more extensive applicative outlook for the treatment of pain, hyperalgesia and allodynia in clinical than classical drugs and ziconotide.

ACKNOWLEDGEMENTS

This work was supported by the National "973" Program of China (No. 2010CB529800) and the Opening Fund of Key Laboratory of Protein Chemistry and Developmental Biology of the Ministry of Education, Hunan Normal University, and the Science and Technology Project of Hunan Province (2012SK3042).

REFERENCES

1. S.P. Liang, X.J. Peng, R.H. Huang and P. Chen, *Life Sci. Res.*, **3**, 299 (1999).
2. Y.C. Xiao and S.P. Liang, *Eur. J. Pharmacol.*, **477**, 1 (2003).
3. Y.C. Xiao, J.Z. Tang, W.J. Hu, C. Maertens, J. Tytgat and S. Liang, *J. Biol. Chem.*, **280**, 12069 (2005).
4. Q. Zhu, S. P. Liang, L. Martin, S. Gasparini, A. Menez and C. Vita, *Biochemistry*, **41**, 11488 (2002).
5. Z. Liu, J. Dai, Z. Chen, W. Hu, Y. Xiao and S. Liang, *Cell Mol. Life Sci.*, **60**, 972 (2004).
6. H.Z. Hu and Z.W. Li, *J. Physiol.*, **501**, 67 (1997).
7. R. Vinegar, J.F. Truax, J.L. Selph and P.R. Johnston, *Handbook of Experimental Pharmacology*, Springer: Verlag, Berlin, Vol. 50/II, p. 208 (1997).
8. T. Kumazawa, K. Mizumura, H. Koda and H. Fukusako, *J. Neurophysiol.*, **75**, 2361 (1996).
9. C.R. Correa, D.J. Kyle, S. Chakraverty and J.B. Calixto, *Br. J. Pharmacol.*, **117**, 552 (1996).
10. V.M. Goettl and A.A. Larson, *Brain Res.*, **780**, 80 (1998).
11. S. Moncada, S.H. Ferreira and J.R. Vane, *Eur. J. Pharmacol.*, **31**, 250 (1975).
12. Y. Ikeda, A. Ueno, H. Naraba and S. Oh-ishi, *Life Sci.*, **69**, 2911 (2001).
13. A.B. Malmberg and T.L. Yaksh, *Pain*, **60**, 83 (1995).
14. K.K. Jain, *Expert. Opin. Investig. Drugs*, **9**, 2403 (2000).
15. R.D. Penn and J.A. Paice, *Pain*, **85**, 291 (2000).